<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493840</url>
  </required_header>
  <id_info>
    <org_study_id>2019013</org_study_id>
    <nct_id>NCT04493840</nct_id>
  </id_info>
  <brief_title>Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Effect of Shenfu Injection on Myocardial Injury in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: A Multicenter, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate whether perioperative use of Shenfu Injection, as compared to&#xD;
      placebo, could reduce infarct size assessed by cardiac magnetic resonance (CMR) in patients&#xD;
      with acute anterior ST-segment elevation myocardial infarction (STEMI) undergoing primary&#xD;
      percutaneous coronary intervention (PCI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shenfu injection is a traditional Chinese medicine formulation containing ginseng (Panax;&#xD;
      family: Araliaceae) and aconite (Radix aconiti lateralis preparata, Aconitum carmichaeli&#xD;
      Debx; family: Ranunculaceae) with Ginsenosides and aconite alkaloids as the main active&#xD;
      ingredients. Its quality is strictly controlled in compliance with the standard of the China&#xD;
      Ministry of Public Health (official approval code: certification number Z20043117; No.&#xD;
      110804, Ya'an, China). Animal studies have shown that Shenfu injection has protective effects&#xD;
      against reperfusion injury through multiple pharmacologic effects, including scavenging free&#xD;
      radicals, inhibiting inflammatory mediators, suppressing cell apoptosis, and inhibiting&#xD;
      calcium overload. However, few data are available regarding its efficacy in humans. We aimed&#xD;
      to determine whether perioperative use of Shenfu injection, as compared to placebo, might&#xD;
      reduce infarct size in patients with STEMI undergoing primary PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size (% of left ventricular mass)</measure>
    <time_frame>5±2 days after PCI</time_frame>
    <description>Infarct size was assessed by performing CMR imaging at 5±2 days after PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction (% of left ventricular mass)</measure>
    <time_frame>5±2 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intramyocardial hemorrhage (% of left ventricular mass)</measure>
    <time_frame>5±2 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of creatine kinase isoenzyme (CK-MB)</measure>
    <time_frame>Immediately after admission (0 hour), and 6, 12, 18, 24, 48, and 72 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of cardiac troponin I</measure>
    <time_frame>Immediately after admission (0 hour), and 6, 12, 18, 24, 48, and 72 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak value of CK-MB and cTnI</measure>
    <time_frame>72 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment resolution (%) according to ECG</measure>
    <time_frame>24 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI flow grade</measure>
    <time_frame>Immediately after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected TIMI frame count (CTFC)</measure>
    <time_frame>Immediately after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI myocardial perfusion grade (TMPG)</measure>
    <time_frame>Immediately after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial salvage index</measure>
    <time_frame>5±2 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area at risk (myocardial edema, % of left ventricular mass)</measure>
    <time_frame>5±2 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-diastolic volume (LVEDV)</measure>
    <time_frame>5±2 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-systolic volume (LVESV)</measure>
    <time_frame>5±2 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>5±2 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular and cerebrovascular events (MACCE, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, emergency revascularization)</measure>
    <time_frame>30 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual events (including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, emergency revascularization, re-hospitalization for heart failure)</measure>
    <time_frame>30 days after PCI</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Slow flow and no flow</measure>
    <time_frame>Index procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Malignant arrhythmia (ventricular fibrillation, ventricular tachycardia, etc.)</measure>
    <time_frame>Index procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Value of high-sensitivity C-reactive protein (Hs-CRP)</measure>
    <time_frame>Immediately after admission (0 hour), and 24, 72 hours and 5 days after PCI</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Value of brain natriuretic peptide (BNP)</measure>
    <time_frame>Immediately after admission (0 hour), and 24, 72 hours and 5 days after PCI</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Myocardial Infarction Dimensional Assessment Scale (MIDAS)</measure>
    <time_frame>6 hours and 30 days after PCI</time_frame>
    <description>0 to 140 scores, higher scores mean worse outcome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Shenfu Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5% Glucose Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shenfu Injection</intervention_name>
    <description>80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.</description>
    <arm_group_label>Shenfu Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Glucose Injection</intervention_name>
    <description>150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.</description>
    <arm_group_label>5% Glucose Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and &lt;75 years.&#xD;
&#xD;
          2. First-time acute anterior STEMI scheduled for primary PCI.&#xD;
&#xD;
          3. ST segment elevation in at least two contiguous precordial leads according to&#xD;
             electrocardiogram (&gt;30 min).&#xD;
&#xD;
          4. Symptoms onset ≤12 hours.&#xD;
&#xD;
          5. The presence of proximal or middle left anterior descending branch (LAD) occlusion&#xD;
             with pre-PCI TIMI flow 0 or 1 according to baseline coronary angiogram.&#xD;
&#xD;
          6. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiogenic shock, serious heart failure (Killip class III or above), malignant&#xD;
             ventricular arrhythmia, or mechanical complications.&#xD;
&#xD;
          2. Post cardiopulmonary resuscitation (CPR) (including cardioversion).&#xD;
&#xD;
          3. Patients who have received thrombolytic therapy or upstream GPIIb/IIIa inhibitors&#xD;
             (GPI).&#xD;
&#xD;
          4. Uncontrolled hypertension (systolic BP ≥180 mm Hg or a diastolic BP ≥110 mmHg).&#xD;
&#xD;
          5. Prior myocardial infarction, PCI or coronary artery bypass graft.&#xD;
&#xD;
          6. Known severe hepatic insufficiency (AST/ALT &gt;3-fold the upper limit of normal value)&#xD;
             or known renal insufficiency.&#xD;
&#xD;
          7. Malignant tumor, lymphoma, HIV-positive, or cirrhosis with life expectancy &lt;1 year.&#xD;
&#xD;
          8. Patients with active bleeding, intracranial hemorrhage, major surgery or trauma within&#xD;
             1 months, or ischemic stroke or transient ischemic attack (TIA) within 6 months.&#xD;
&#xD;
          9. History of anemia (hemoglobin&lt;90g/L) or thrombocytopenia (thrombocyte&lt;100×109/L).&#xD;
&#xD;
         10. Patients who require simultaneous intervention of left main disease during primary PCI&#xD;
             or those with multi-vessel disease who plan to intervene in non-culprit vessels within&#xD;
             7 days (simultaneous or staged).&#xD;
&#xD;
         11. Scheduled for CABG within one month after randomization.&#xD;
&#xD;
         12. Pregnancy, lactation, or potentially fertile women.&#xD;
&#xD;
         13. Patients who have known to be allergic to Shenfu Injection or its components or&#xD;
             patients with serious adverse effect.&#xD;
&#xD;
         14. Patients with contraindication to CMR (metal foreign body in the body, claustrophobia,&#xD;
             etc.).&#xD;
&#xD;
         15. Participation in other clinical trial in recent 3 months.&#xD;
&#xD;
         16. Patients who cannot complete this trial or comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shao-Ping Nie, MD, PhD</last_name>
    <phone>86-10-84005256</phone>
    <email>spnie@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Wang, MD</last_name>
    <phone>86-10-84005255</phone>
    <email>spaceeye123@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <phone>86-10-84005256</phone>
      <email>spnie@ccmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiao Wang, MD</last_name>
      <phone>86-10-84005255</phone>
      <email>spaceeye123@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shao-Ping Nie</investigator_full_name>
    <investigator_title>Professor of Medicine, Director, Emergency &amp; Critical Care Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

